Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside
- PMID: 15632040
Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside
Abstract
The study was performed to compare the (18)F-labeled nitroimidazole compound fluoroazomycin arabinoside ((18)F-FAZA) with the standard hypoxia tracer fluoromisonidazole ((18)F-FMISO) in detection of tumor tissue hypoxia and to verify the oxygenation dependency of (18)F-FAZA uptake.
Methods: Biodistribution of (18)F-FAZA was studied at various time points in EMT6 tumor-bearing BALB/c mice and in AR42J and A431 tumor-bearing nude mice and compared with that of (18)F-FMISO. The presence of tumor tissue hypoxia was verified in 5 EMT6 and 5 AR42J tumors using an oxygen-sensing needle electrode system. To evaluate the oxygenation dependency of (18)F-FAZA uptake, using the Munich prototype animal PET scanner, 2 serial PET scans were performed in 13 A431 tumor-bearing nude mice breathing pure oxygen or room air on 1 d and then selecting the other oxygen breathing condition on the following day. In addition, digital autoradiography was performed with EMT6 tumor-bearing (18)F-FAZA-dosed, nude mice breathing either room air (n = 8) or carbogen (n = 9).
Results: Tissue partial pressure of oxygen (Po(2)) electrode measurements revealed that tumor hypoxia was present under room air breathing in EMT6 (tissue Po(2) = 2.9 +/- 2.6) and AR42J tumors (tissue Po(2) = 0.4 +/- 0.2), which was significantly lower compared with that of reference tissue (tissue Po(2) = 25.8 +/- 6.7 and tissue Po(2) = 29.0 +/- 3.0 [mean +/- SD], respectively; P < 0.01). In all tumor models, (18)F-FAZA displayed significantly higher tumor-to-muscle and tumor-to-blood ratios compared with (18)F-FMISO, indicating a faster clearance of (18)F-FAZA from normal tissues. In AR42J tumors, (18)F-FAZA tumor-to-normal ratios were found to increase over time. Serial animal (18)F-FAZA PET studies showed that the tumor-to-background ratio was significantly higher in animals breathing room air compared with that of animals breathing pure oxygen (7.3 +/- 2.3 vs. 4.2 +/- 1.2, respectively; P < 0.001). Similarly, autoradiography showed significantly higher tumor-to-muscle ratios in mice breathing room air compared with those of animals breathing carbogen (5.3 +/- 0.8 vs. 2.2 +/- 0.8; respectively; P < 0.02).
Conclusion: (18)F-FAZA shows superior biokinetics and is, thus, a promising PET tracer for the visualization of tumor hypoxia. This study also verified a hypoxia-specific uptake mechanism for (18)F-FAZA in murine tumor models.
Similar articles
-
Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.J Pharm Pharm Sci. 2007;10(2):203-11. J Pharm Pharm Sci. 2007. PMID: 17706178
-
Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.Eur J Nucl Med Mol Imaging. 2004 Jan;31(1):117-28. doi: 10.1007/s00259-003-1322-y. Epub 2003 Oct 2. Eur J Nucl Med Mol Imaging. 2004. PMID: 14523586
-
A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):351-9. doi: 10.1016/j.ijrobp.2014.09.045. Epub 2014 Dec 6. Int J Radiat Oncol Biol Phys. 2015. PMID: 25491505
-
Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside (18F-FAZA)-PET: a review.Clin Nucl Med. 2014 Jan;39(1):44-8. doi: 10.1097/RLU.0000000000000286. Clin Nucl Med. 2014. PMID: 24152663 Review.
-
Hypoxia imaging agents labeled with positron emitters.Recent Results Cancer Res. 2013;194:285-99. doi: 10.1007/978-3-642-27994-2_15. Recent Results Cancer Res. 2013. PMID: 22918765 Review.
Cited by
-
PET imaging of hypoxia using [18F]HX4: a phase I trial.Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1663-8. doi: 10.1007/s00259-010-1437-x. Epub 2010 Apr 6. Eur J Nucl Med Mol Imaging. 2010. PMID: 20369236 Clinical Trial.
-
Kinetic Evaluation of the Hypoxia Radiotracers [18F]FMISO and [18F]FAZA in Dogs with Spontaneous Tumors Using Dynamic PET/CT Imaging.Nucl Med Mol Imaging. 2023 Feb;57(1):16-25. doi: 10.1007/s13139-022-00780-4. Epub 2022 Oct 11. Nucl Med Mol Imaging. 2023. PMID: 36643946 Free PMC article.
-
Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1566-75. doi: 10.1007/s00259-007-0424-3. Epub 2007 Apr 20. Eur J Nucl Med Mol Imaging. 2007. PMID: 17447061
-
Synthesis of a 2-nitroimidazole derivative N-(4-[18F]fluorobenzyl)-2-(2-nitro-1H-imidazol-1-yl)-acetamide ([18 F]FBNA) as PET radiotracer for imaging tumor hypoxia.EJNMMI Radiopharm Chem. 2022 Jun 13;7(1):13. doi: 10.1186/s41181-022-00165-0. EJNMMI Radiopharm Chem. 2022. PMID: 35697954 Free PMC article.
-
Radiotherapy Planning and Molecular Imaging in Lung Cancer.Curr Radiopharm. 2020;13(3):204-217. doi: 10.2174/1874471013666200318144154. Curr Radiopharm. 2020. PMID: 32186275 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources